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YClOSPORINE (CsA) is a potent C. munosuppressive agent that is metab-I~lm 'marily in the liver by hydroxylation 01.- pn 1 bol' ltd N-dcmethylation. esA meta Ites are 
• ted into the bile and eliminated through fl~ tcstinal tract. 2 Recently the isolation of 
,he 10 b'l f I' C A metabolites in human I e rom Iver 
• nlant recipients has been reported.J.4 
trans" d 'bed h . Rc)!Ulno et al have also . escn t ree pn-
ry metabolites of CsA In the blood of renal 11111 5 
.J1ograft recipients. . .. 
The immunosuppressIve actIvity of several 
CIA metabolites has been demonstrated in 
vitro using lymphocyte proliferation assays, 
luch as mitogen responses, and in mixed lym-
phocyte reaction (MLR) culturesY It has 
been shown that fractions of bile contain CsA 
metabolites with significant in vitro immuno-
suppressive effects on the secondary prolifera-
tion of aIloreactive T cells generated from 
MLR or propagated from transplant biop-
sies.' Certain metabolites may also inhibit 
interIeukin 2 (IL 2) production in MLR and 
the generation of cytotoxic T cells.6 Particu-
larly, metabolites Ml7 and Ml with single 
hydroxylations of amino acids in positions 1 
and 9, respectively, exhibit considerable 
immunosuppressive activity in vitro that 
approaches that produced by CsA.6 In con-
trast, metabolites M8 and M21 exhibit mark-
edly reduced in vitro immunosuppressive 
activity relative to that of the parent com-
pound.6 Metabolite M8 is hydroxylated at 
both amino acids 1 and 9, and M21 has an 
N-methylated amino acid at position 4. 
Recent observations have suggested rela-
tively greater inhibitory effects of CsA and its 
active metabolites on the secondary prolifera-
tion of alloreactive T cells than on primary T 
cell alloactivation that occurs in MLR.7 
Another important aspect in assessing the 
immunosuppressive effect CsA metabolites 
relates to differences in the drug sensitivity of 
various T cell populations. Several investiga-
tors have reported differences among individ-
uals in esA sensitivity of peripheral blood 
lymphocytes activated by mitogens or 
MLR.8,9 Similarly, differences in esA sensi-
tivity have also been observed in alloreactive 
lymphocyte clones generated from MLR.7 
This report describes studies on the in vitro 
sensitivity of alloreactive T cells isolated from 
graft biopsies to CsA and its metabolites. 
Moreover, a synergism in terms of their anti-
proliferative effect was observed with combi-
nations of low doses of esA and its active 
metabolite, M 17. 
MATERIALS AND METHODS 
Lymphocyte Proliferation Assays 
MLR-induced activation. Unidirectional human 
MlR cultures were set up with \05 responder and 105 
irradiated (2.000 rad) stimulator cells in a volume of 200 
pl tissue culture medium (TCM) supplemented with 
10% human serum for six days.'o During the final 20 
hours of incubation, each culture was labeled with I j./Ci 
of 3H-thymidine. The cultures were harvested and 
counted in a liquid scintillation counter. 
PLT testing of alloreactive T cells. Alloreactive 
human T cell clones were generated from in vitro MLR 
cultures as previously described.'o Alloreactive lympho-
cyte cultures were also propagated from human heart and 
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liver biopsies in the presence of IL 2 as previously 
reported.,,·12 Secondary proliferation of alloreactive cells 
was assessed in a three-day primed lymphocyte test 
(PL n, wherein 10' responder ceUs were incubated with 
lOS irradiated (2,000 rad) stimulator cells. 10 Lymphocyte 
proliferation was assessed by 'H-thymidine incorporation 
as described above. 
Drug sources. CsA was obtained from Sandoz (Ba-
sel, Switzerland), and was dissolved in ethanol and fur-
ther diluted in rCM to various concentrations. CsA 
metabolites were obtained according to previously 
described methods.' Briefly, pooled bile collected from T 
tubes of adult liver transplant recipients was extracted 
with diethyl ether, and mUltiple aliquots of the extract 
were injected onto a high-pressure liquid chromato-
graphic (HPLC) system which separated the individual 
components. Thirteen individual fractions were collected, 
purified, and tested for their immunosuppressive effect on 
lymphocyte proliferation. 
Dose effects of CsA and its metabolites on lymphocyte 
proliferation. The inhibitory effects of CsA and its 13 
different bile-derived metabolite fractions were assessed 
at concentrations of drugs ranging from 0.005 to 5 Ilg/mL 
on MLR activation and the PL T responses of alloreactive 
lymphocytes. The results were expressed as percent inhi-
bition using the formula: 
[ cpm with drug ] % inhibition - 1 - . h x 100. 
cpm wit out drug 
RESULTS 
Effect of CsA and its Bile-Derived 
Metabolites on T Cell AI/oresponses 
Inhibition of MLR response. Thirteen 
separate HPLC fractions were tested for their 
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immunosuppressive effects on the primary 
MLR response (Fig I B). Greater than 40% 
MLR inhibition was observed with five frac-
tions, including bile-derived metabolites M17, 
MI, and M21, and two unidentified fractions 
(4 and 6). The MI7 metabolite (fraction 8) 
exhibited inhibitory activity comparable with 
that observed with 5 ~g/mL and 0.5 ~g/mL of 
CsA (Fig IA)_ On the other hand, no signifi-
cant inhibitory activity was detected for any 
of the other fractions at concentrations of 0.5 
~g/mL and less. These observations demon-
strate that several HPLC fractionated CsA 
meta bolites found in bile have significantly 
inhibitory effects on MLR-induced prolifera-
tion. 
Inhibition oj PLT responses of alloreactive 
T cell clones. Two class II-specific alloreac-
tive T cell clones HA6 (anti-DRw6) and 
DB29 (anti-DQwl) were tested for PLT 
responses in the presence of different doses of 
CsA (Fig 2). A dose of 25 ng/mL of CsA was 
sufficient to inhibit greater than 90% of the 
PLT response of clone HA6, whereas clone 
D 829 required a tenfold higher dose of CsA to 
achieve the same degree of inhibition. This 
difference in CsA sensitivity between clones 
HA6 and D829 was observed also for some of 
the thirteen different bile-derived CsA metab-
olite fractions (Fig 3). Although M 17 had an 
inhibitory effect equal to that of CsA on both 
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Fig 1. Effect of CsA and its bile-derived metabolites on MLR response cpm backgrOUnd. (A) Dose effect of CsA 
and metabolite. M17. M1. M21. M13. and fraction 4. (Bllnhibition of MlR response in the presence of 51'g/mL of 
CsA metabolite fractions. MLR response was 23.168 ± 1.335 cpm. 
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Fig 2. Dose effect of CsA on PL T response of 
alloreactive T cell clones HA6 and 0829. PL T response 
of clones HA6 12.089 ± 1.301 and 0829 26.377 ± 
1.376. 
clones (HA6 and OB29), the M21 metabolite 
only inhibited the CsA-sensitive clone HA6 
but not the CsA-resistant clone DB29. Simi-
larly, the inhibition observed with M 1 (frac-
tion 9) was greater using HA6 cells than it 
was with the OB29 cells. 
These data suggest that differences in sen-
sitivity among alloreactive T cell clones for 
CsA inhibition of proliferative response may 
be seen also with CsA metabolites. 
Effect of CsA metabolites on lymphocyte 
cultures propagated from liver and heart 
allograft biopsies. Alloreactive lymphocyte 
cultures propagated from liver and heart allo-
graft biopsies were tested for their donor-
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specific proliferative responses in the presence 
of CsA and three to four bile-derived metabo-
lites. As shown in Fig 4, metabolites M 17, 
MI, M21, and MI8 at a dose of 5 Itg/mL 
significantly inhibited the PL T activity of 
lymphocyte cultures obtained from a liver 
allograft biopsy (LB). In addition, metabo-
lites M 17 and M I exhibited inhibitory activ-
ity comparable at all doses to that observed 
with the parent compound, CsA. On the other 
hand, a lymphocyte culture grown from a 
heart biopsy (HB) required a 50-fold higher 
dose of CsA than did the LB cells to achieve 
the same degree of inhibition (Fig 5); this HB 
lymphocyte culture was also less sensitive to 
the various CsA metabolites studied than 
were the cells isolated from the LB. As can be 
seen in Fig 5, only M17 and M21 significantly 
inhibited the PL T response of cells isolated 
from an HB at a concentration of 2.5 ~g/mL, 
whereas M 18 had no effect. 
These results demonstrate that several CsA 
metabolites present in bile have a significant 
inhibitory effect on alloreactive T cells 
derived from biopsies of human allografts. 
Similar sensitivity patterns were noted with 
CsA and the active CsA metabolites . 
Effect of CsA metabolites on donor-
specific PLT response of sequential HO lym-
phocyte cultures. Four heart biopsy lym-
phocyte cultures (HBI, HB2, HB3, and HB4) 
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I 2 3 ~ 5 (I 7 a 9 10 II 12 13 
FRACTION IU18(R 
118 
S 
InhIbItion 
of PLT 
Response 
ZEEVI ET AL 
O~!-------+-------+-------+------~ 
Fig 4. Dose effect of CsA 
end metabolites M17. M1. 
M18. and M21 on PL T response 
of Iymphocytas propagated 
from an LB. The donor-specific 
PL T response of LB cells was 
20.330 ± 1.507 cpm. 
'5 5 25 
ug/ml drug 
were obtained from a heart transplant patient 
at posttransplant days 44, 58, 63, and 69, 
respectively. These lymphocyte cultures were 
tested for PL T responses in the presence of 
various concentrations of esA and M17. As 
shown in Fig 6A, HB4 exhibited the highest 
esA sensitivity requiring a low dose of om 
~g/mL for 50% inhibition of PLT activity 
(LD50 = 0.01 ~g/mL). The two cultures 
HB I and HB3 were less affected by esA and 
required a tenfold increase in the esA dose to 
achieve a 50% reduction in their PLT 
responses (LD50 = 0.1 ~g/mL). The lympho-
cyte culture HB2 exhibited an intermediate 
response to esA with an LD50 of 0.05 p.g/ 
mL. 
Similar patterns of sensitivity among HB 
100 
005 
cultures from this patient were also observed 
for the M 17 metabolite (Fig 6B). At a concen-
tration of 5 p.g/mL, M 17 was strongly inhibi-
tory to all four HB cultures. The esA-
sensitive culture HB4 was significantly inhib-
ited by low doses of M17 (LD50 = 0.025 
p.g/mL) whereas the two esA-resistant lym-
phocyte cultures (HBI and HB3) required 
20-fold higher concentrations of M I 7 
(LD50 = 0.5 p.g/mL). 
All four HB lymphocyte cultures were 
obtained during a period of acute rejection, 
and the patient received treatment with rabbit 
anti thymocyte globulin (RATG) and methyl-
prednisolone. 
These observations demonstrate differences 
in esA and M17 sensitivity of lymphocyte 
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Fig 6. Dose effect of CsA 
and metabolites M17. M21. and 
M18 on donor-specific PL T 
activity of HB-grown lympho-
cytes. The PL T response of HB 
culture was 60.900 ± 2.913 
cpm. 
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Fig 6. Inhibition of PL T reactivity of four lymphocyte culture. propegeted from .equentlal HI. HB'. HB2. H13. 
end HB4 in the presence of (A) CsA end (II M17. Donor-specific PL T response. of the.e HI lymphocyte. were: H11. 
19.B50 ± 2.024 cpm; H12. 11.504 ± .. 12 cpm; H13, 43.750 ± 705 cpm; HB4. 13.053 ± 872 cpm. 
cultures propagated from heart transplant 
biopsies obtained from the same patient at 
various intervals posttransplantation. 
Effect of low doses of CsA and M 17 on 
PLT activity on HB-grown cells. Addition 
of esA or MI7 at concentrations of 0.025 
~g/mL and 0.25 ~g/mL (or less), respec-
tively. had no significant inhibitory effect on 
the PLT response of the HB lymphocyte cul-
ture (Fig 5). However, a combination of these 
low doses of esA and M 1 7 induced strong 
inhibition (>70%) (Fig 7). The synergistic 
50 1 
t) 1 
! 
0 60 Q. 
., 
t) 
'-
... 
..J 
Q. 40 
..... 
0 
c 
0 
.-
-:s 20 
:E 
c 
~ 
0 
0.25 0.05 
effect produced with the combination of esA 
and MI7 could be demonstrated also with 
tenfold lower doses of M 17 (Fig 7). 
DISCUSSION 
These findings demonstrate that there are 
differences between activated T cells in their 
sensitivity to esA and its metabolites. The 
present studies focused on the secondary pro-
liferative responses of cloned alloreactive T 
cells and T cell lines propagated from liver 
and heart transplant biopsies. 
[J M17 
0 CsA (}.O25 
• CsA+f117 
0.025 
ug/ml Mt7 
Fig7. Effect of combination of low doses of CsA end M17 on PL T response of activated T cen propagated from a 
heart biopsy. Donor-specific PL T re.pon.e 60.900 ± 2.913 cpm. 
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The data extend the findings by Manca et 
al9 who studied MLR-derived T cell lines and 
our own observations regarding differences in 
CsA sensitivity of alloreactive T cells obtained 
from MLR cultures or isolated from allograft 
biopsies. 7 In secondary proliferative, an 
MLR-derived CsA-sensitive T cell clone was 
more inhibited by CsA metabolites than was 
another MLR-derived CsA-resistant clone. 
Similar sensitivity patterns were found with 
lymphocyte cultures propagated from trans-
plant biopsies. These cultures often exhibit 
allospecificity towards donor HLA anti-
gensll.12.14.1S and have been shown to be partic-
ularly sensitive to metabolites M 17, M I, and 
M21 obtained from bile but always to a lesser 
extent than that observed with the parent 
compound, CsA. The present findings are 
concordant with those of Freed et al6 who 
demonstrated that M17, MI, and M21 are 
active immunosuppressive CsA metabolites as 
determined in mitogen-induced lymphocyte 
responses, MLR culture and the IL 2 release 
assays. 
The primary goal of the present studies was 
to obtain a better understanding of the in situ 
effect of CsA and its metabolites on lympho-
cytes proliferative response studied using cells 
isolated from allograft biopsies. These studies 
recognize the fact that most allografts are 
infiltrated by alloreactive T cells that can 
undergo clonal expansion and activation and 
produce rejection. 
Because CsA appears to primarily inhibit 
lymphocyte expansion, its effectiveness in the 
treatment of rejection depends on the sensitiv-
ity of the infiltrating cells present in the 
allograft to CsA and its various metabolites. 
Recently developed methodologies of propa-
gating infiltrating T lymphocytes from allo-
graft biopsies have provided a unique opportu-
nity to evaluate this concept. A good example 
has been the heart transplant patient 
described in this report from whom cells pro-
pagated from four different endomyocardial 
biopsies were studied. The relatively CsA-
resistant lymphocyte cultures propagated 
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from biopsies HBI, HB2, and HB3 were 
obtained during a rejection crisis. Lympho-
cyte culture HBI was obtained at the onset of 
a rejection episode whereas HB2 and HB3 
were both taken after treatment of rejection 
with RA TG and methylprednisolone, respec-
tively. 
As shown before/lymphocytes grown from 
biopsies posttreatment for rejection contain 
residual CsA-resistant cell populations. On 
the other hand, culture HB4, which was taken 
when the rejection crisis was brought under 
control, propagated only a CsA-sensitive pop-
ulation. This patient is now 115 days post-
transplant with no clinical evidence of rejec-
tion. More studies are needed to investigate 
the correlation between CsA sensitivity of 
lymphocytes isolated from allograft biopsies 
and transplant outcome. 
The effectiveness of CsA therapy might 
depend highly upon the immunosuppressive 
effects' of combinations of individual metabo-
lites and the parent compound. This may 
explain the presence of MLR inhibitory activ-
ity present in the serum of renal transplant 
recipients when low levels of CsA have been 
found. '6 It is possible that low levels of CsA in 
combination with CsA metabolites may be an 
adequate immunosuppressive when the con-
centrations of CsA or any of its metabolites 
alone would not be adequately immunosup-
pressive. 
Such a synergism between CsA and its 
metabolites has not been reported previously. 
M 17, a major metabolite of CsA, is present in 
concentrations greater than that of CsA in the 
peripheral blood of kidney, liver, and heart 
transplant recipients,s.1) and our in vitro data 
indicate that its antiproliferative effect is 
increased in the presence of low levels of CsA. 
Recently a synergism between low doses of 
CsA and a new immunosuppressive agent, 
FK506, has been reported. '7 Little is known 
about the mechanism of synergism between 
CsA and M 17 or FK506. Both drugs (CsA 
and FK506) appear to act through a common 
mechanism consisting of the inhibition of IL 2 
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determine the mechanism responsible for this 
synergism, 
In conclusion. a comprehensive therapeutic 
strategy should include monitoring of not only 
CsA but also the active metabolites of CsA 
and must recognize that differences in lym~ 
phocyte sensitivity to these drugs occurs par-
ticularly in relation to the occurrence and 
treatment of allograft rejection, 
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